An interventional study of Functional Imaging previous the second course and Functional Imaging previous the surgery in Ovarian Cancer, sponsored by Institut Bergonié. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-21.
Sponsored by Institut Bergonié · Not applicable, Interventional, and Diagnostic
This study evaluates the therapeutic response by modern FMRI and PET techniques with the perspective to exploit multimodal data (fusion MRI/PET). The Sponsor would like to optimize the respective performances and to define the early assessment criteria, at the first detox, of the treatment efficacy, with and without antiangiogenic agent.
This study evaluates the therapeutic response by modern FMRI and PET techniques with the perspective to exploit multimodal data (fusion MRI/PET). The Sponsor would like to optimize the respective performances and to define the early assessment criteria, at the first detox, of the treatment efficacy, with and without antiangiogenic agent. It is a single center evaluation of the study treatment.
2,695 studies on the registry are indexed under Ovarian Neoplasms; 727 are open to participants now.
This study's enrollment of 11 is below the median of 60 across 2,030 interventional studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →Institut Bergonié is the lead sponsor of 119 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
A pilot study to evaluate the response to neoadjuvant chemotherapy for advanced ovarian cancer by multimodal functional imaging (Fusion MRI and FDG-PET-CT)
Device: Functional Imaging previous the second course · Device: Functional Imaging previous the surgery
Functional Imaging before and after 1 cycle of chemotherapy treatment, in the previous 4 days before the second course: PET1 and MRI1
Functional Imaging after 4 cycles of chemotherapy treatment, in the 3 weeks after the chemotherapy, before the interval surgery: PET4 and MRI4 The RECIST evaluation will be done, usually, by scanner to 4 courses of chemotherapy before the surgery interval
Inter-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Individual Intra-class Correlation Coefficients by Location
Individual intra-class correlation coefficients by location (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter SUVmax of functional imaging positron emission tomography. The functional imaging positron emission tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: Pre-therapeutic
Inter-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Average Intra-class Correlation Coefficients by Location
Average intra-class correlation coefficients(Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter SUVmax of functional imaging positron emission tomography. The functional imaging positron emission tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: Pre-therapeutic
Inter-rater Reliability of Positron Emission Tomography (PET) Metabolic Tumoral Volume (MTV) - Individual Intra-class Correlation Coefficients by Location
Individual intra-class correlation coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter MTV of functional imaging Positron Emission Tomography. The functional imaging positron emission tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: Pre-therapeutic
Inter-rater Reliability of Positron Emission Tomography (PET) Metabolic Tumoral Volume (MTV) - Average Intra-class Correlation Coefficients by Location
Average intra-class correlation coefficients (Absolute agreement) arepresented by location to evaluate the reliability between observers of quantization parameter MTV of functional imaging Positron Emission Tomography. The functional imaging Positron Emission Tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: Pre-therapeutic
Inter-rater Reliability of Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter ADC of functional imaging Magnetic Resonance Imaging. The Magnetic Resonance Imaging will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: Pretherapeutic
Inter-rater Reliability of Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC) - Average Intra-class Correlation Coefficients by Location
Average intra-class correlation coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter ADC of functional imaging Magnetic Resonance Imaging. The Magnetic Resonance Imaging will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: Pretherapeutic
Inter-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter SUVmax of functional imaging Positron Emission Tomography (PET). The functional imaging Positron Emission Tomography (PET) will be interpreted twice by radiologist and nuclear medicine specialist.
Time frame: After one cycle of chemotherapy, 3 weeks
Inter-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Average Intra-class Correlation Coefficients by Location
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter SUVmax of functional imaging Positron Emission Tomography (PET) . The functional imaging Positron Emission Tomography (PET) will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: After one cycle of chemotherapy, 3 weeks
Inter-rater Reliability of Positron Emission Tomography (PET) Metabolic Tumoral Volume (MTV) - Individual Intra-class Correlation Coefficients by Location
Individual intra-class correlation coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter MTV of functional imaging Positron Emission Tomography (PET). The functional imaging Positron Emission Tomography (PET) will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: After one cycle of chemoterapy, 3 weeks
Inter-rater Reliability of Positron Emission Tomography (PET) Metabolic Tumoral Volume (MTV) - Average Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter MTV of functional imaging Positron Emission Tomography (PET). The functional imaging Positron Emission Tomography (PET) will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: After one cycle of chemotherapy, 3 weeks
Inter-rater Reliability of Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: After one cycle of chemotherapy, 3 weeks
Inter-rater Reliability of Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC) - Average Intra-class Correlation Coefficients by Location
Average intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: After one cycle of chemotherapy, 3 weeks
Inter-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter SUVmax of functional imaging positron emission tomography (PET) . The functional imaging positron emission tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: After four cycles of chemotherapy, 12 weeks
Inter-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Average Intra-class Correlation Coefficients by Location
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter SUVmax of functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: After four cycles of chemotherapy, 12 weeks
Inter-rater Reliability of Positron Emission Tomography (PET) Metabolic Tumoral Volume (MTV) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter MTV of functional imaging Positron Emission Tomography (MTV). The functional imaging Positron Emission Tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: After four cycles of chemoterapy, 12 weeks
Inter-rater Reliability of Positron Emission Tomography (PET) Metabolic Tumoral Volume (MTV) - AverageIntra-class Correlation Coefficients by Location
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter MTV of functional imaging Positron Emission Tomography (PET). The functional imaging Positron Emission Tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: After four cycles of chemotherapy, 12 weeks
Inter-rater Reliability of Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter ADC of functional imaging Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: After four cycles of chemotherapy, 12 weeks
Inter-rater Reliability of Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC) - Average Intra-class Correlation Coefficients by Location
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter of ADC functional imaging Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
Time frame: After four cycles of chemotherapy, 12 weeks
Intra-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter ADC of functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: Pre-therapeutic
Intra-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Average Intra-class Correlation Coefficients by Location
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter SUVmax of functional imaging positron emission tomography (PET) . The imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: Pre-therapeutic
Intra-rater Reliability of Positron Emission Tomography (PET) Metabolic Tumoral Volume (MTV) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameters functional imaging Positron Emission Tomography (MTV). The functional imaging Positron Emission Tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: Pre-therapeutic
Intra-rater Reliability of Positron Emission Tomography (PET) Metabolic Tumoral Volume (MTV) - Average Intra-class Correlation Coefficients by Location
Average Intra-class Correlation Coefficients by Location (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameters MTV of functional imaging Positron Emission Tomography. The functional imaging Positron Emission Tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: Pre-therapeutic
Intra-rater Reliability of Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: Pretherapeutic
Intra-rater Reliability of Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC) - Average Intra-class Correlation Coefficients by Location
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI) . The Magnetic Resonance Imaging will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: Pretherapeutic
Intra-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter SUV max of functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: After one cycle of chemoterapy, 3 weeks
Intra-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Average Intra-class Correlation Coefficients by Location
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter SUVmax of functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: After once cycle of chemoterapy, 3 weeks
Intra-rater Reliability of Positron Emission Tomography (PET) Metabolic Tumoral Volume (MTV) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter MTV of functional imaging Positron Emission Tomography (PET). The functional imaging Positron Emission Tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: After one cycle of chemoterapy, 3 weeks
Intra-rater Reliability of Positron Emission Tomography (PET) Metabolic Tumoral Volume (MTV) - Average Intra-class Correlation Coefficients by Location
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter MTV of functional imaging Positron Emission Tomography (PET). The functional imaging Positron Emission Tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: After once cycle of chemotherapy, 3 weeks
Intra-rater Reliability of Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: After one cycle of chemotherapy, 3 weeks
Intra-rater Reliability of Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC) - Average Intra-class Correlation Coefficients by Location
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: After one cycle of chemotherapy, 3 weeks
Individual Intra-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter SUVmax of functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: After four cycles of chemoterapy, 12 weeks
Intra-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Average Intra-class Correlation Coefficients by Location
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter SUVmax of functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: After four cycles of chemoterapy, 12 weeks
Intra-rater Reliability of Positron Emission Tomography (PET) Metabolic Tumoral Volume (MTV) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter MTV functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: After four cycle of chemoterapy, 12 weeks
Intra-rater Reliability of Positron Emission Tomography (PET) Metabolic Tumoral Volume (MTV) - Average Intra-class Correlation Coefficients by Location
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter MTV functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: After four cycles of chemotherapy, 12 weeks
Intra-rater Reliability of Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC) - Individual Intra-class Correlation Coefficients by Location
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter ADC of functional imaging Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: After four cycles of chemotherapy, 12 weeks
Intra-rater Reliability of PET Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC) - Average Intra-class Correlation Coefficients by Location
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
Time frame: After four cycles of chemotherapy, 12 weeks
Spearman Correlation Coefficient Between Marker CA125 and the Relative Variations (Between Pretherapeutic and After One Cycle of Chemotherapy) of the PET Parameters (SUVmax, MTV, SUVN, SUL and TLG)
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy). In other words, without paying attention to assessment times and the location of the lesion, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyse. The appearance of new lesions (not present at baseline) has not been taken into account in the calculation of relative variations. The disappearance of pre-existing lesions at baseline has been taken into account in the calculation of relative variations. Relative variations has been calculated as the difference between the values collected after 1 cycle of chemotherapy and the pre-therapeutic value divided by the pre-therapeutic value.
Time frame: After one cycle of chemotherapy, 3 weeks
Spearman Correlation Coefficient Between Marker CA125 and the Relative Variations (Between Pre-therapeutic and After Four Cycles of Chemotherapy) of the PET Parameters (SUVmax, MTV, SUVN, SUL and TLG)
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy). In other words, without paying attention to assessment times and the location of the lesion, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyse. The appearance of new lesions (not present at baseline) has not been taken into account in the calculation of relative variations. The disappearance of pre-existing lesions at baseline has been taken into account in the calculation of relative variations. Relative variations has been calculated as the difference between the values collected after 4 cycles of chemotherapy and the pre-therapeutic value divided by the pre-therapeutic value.
Time frame: After four cycles of chemotherapy, 12 weeks
Spearman Correlation Test Between the Relative Variation of Apparent Diffusion Coefficient (ADC) and Marker CA125
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. The appearance of new lesions (not present at baseline) has not been taken into account in the calculation of relative variations. The disappearance of pre-existing lesions at baseline has been taken into account in the calculation of relative variations. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles of chemotherapy and the pre-therapeutic value divided by the pre-therapeutic value.
Time frame: After one and four cycle(s) of chemotherapy (after 3 and 12 weeks)
Complete Surgery Resection
Time frame: Interval surgery visit: up to 3 weeks after cycle 4 of chemotherapy and until the day before the surgery
Descriptive Statistics of Relative Variations of PET Parameter SUVmax by Response as Per RECIST V1.1
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
Time frame: After one cycle of chemotherapy, 3 weeks
Descriptive Statistics of Relative Variations of PET Parameter SUVmax by Response as Per RECIST V1.1
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. RRelative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
Time frame: After four cycles of chemotherapy, 12 weeks
Descriptive Statistics of Relative Variations of PET Parameter MTV by Response as Per RECIST V1.1
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
Time frame: After four cycles of chemotherapy, 12 weeks
Descriptive Statistics of Relative Variations of PET Parameter MTV by Response as Per RECIST V1.1
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
Time frame: After one cycle of chemotherapy, 3 weeks
Descriptive Statistics of Relative Variations of PET Parameter SUVN by Response as Per RECIST V1.1
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
Time frame: After one cycle of chemotherapy, 3 weeks
Descriptive Statistics of Relative Variations of PET Parameter SUVN by Response as Per RECIST V1.1
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
Time frame: After four cycles of chemotherapy, 12 weeks
Descriptive Statistics of Relative Variations of PET Parameter TLG by Response as Per RECIST V1.1
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
Time frame: After one cycle of chemotherapy, 3 weeks
Descriptive Statistics of Relative Variations of PET Parameter TLG by Response as Per RECIST V1.1
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
Time frame: After four cycles of chemotherapy, 12 weeks
Descriptive Statistics of Relative Variations of PET Parameter SUL by Response as Per RECIST V1.1
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
Time frame: After one cycle of chemotherapy, 3 weeks
Descriptive Statistics of Relative Variations of PET Parameter SUL by Response as Per RECIST V1.1
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
Time frame: After four cycles of chemotherapy, 12 weeks
Descriptive Statistics of Relative Variations of MRI Parameter ADC by Response as Per RECIST V1.1
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
Time frame: After one cycle of chemotherapy, 3 weeks
Descriptive Statistics of Relative Variations of MRI Parameters ADC by Response as Per RECIST V1.1
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
Time frame: After four cycles of chemotherapy, 12 weeks
Peritoneal Extent Assessed by Fagotti Score Using MRI Data
The Fagotti score ranges from 0 to 14 and is used to evaluate the peritoneal damage of patients. This score was collected during pretherapy and after 4 cycles of chemotherapy. The higher the stage number is, the further the cancer has spread. The Fagotti questionnaire has 7 items. A subscale value of 0 or 2 is assigned depending on whether the disease is present in those specific sites : large omentum, peritoneal carcinosis , diaphragmatic carcinosis, mesenteric retraction, intestinal infiltration, stomach infiltration,liver metastases. The sum of subscale values corresponds to Fagotti score.
Time frame: Pre-therapeutic
Peritoneal Extent Assessed by Fagotti Score Using MRI Data
TThe Fagotti score ranges from 0 to 14 and is used to evaluate the peritoneal damage of patients. This score was collected during pretherapy and after 4 cycles of chemotherapy. The higher the stage number is, the further the cancer has spread. The Fagotti questionnaire has 7 items. A subscale value of 0 or 2 is assigned depending on whether the disease is present in those specific sites : large omentum, peritoneal carcinosis , diaphragmatic carcinosis, mesenteric retraction, intestinal infiltration, stomach infiltration,liver metastases. The sum of subscales corresponds to Fagotti score.
Time frame: Interval surgery visit: up to 3 weeks after cycle 4 of chemotherapy and until the day before the surgery
Overall Survival
Time frame: 10 months
Progression-free Survival as Per RECIST v1.1
Time frame: 9, 13, 14 months
| Milestone | Functional Imaging |
|---|---|
| Started | 11 |
| Completed | 10 |
| Not completed | 1 |
| Withdrew: Protocol violation | 1 |
Individual intra-class correlation coefficients by location (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter SUVmax of functional imaging positron emission tomography. The functional imaging positron emission tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.992 (0.969 to 0.998) |
| Sus-mesocolic | 0.997 (0.987 to 0.999) |
| Sub-mesocolic | 0.983 (0.937 to 0.996) |
| Pelvis | 0.997 (0.988 to 0.999) |
| Viscera | 0.951 (0.826 to 0.987) |
| ADP | 0.960 (0.853 to 0.990) |
Average intra-class correlation coefficients(Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter SUVmax of functional imaging positron emission tomography. The functional imaging positron emission tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.996 (0.984 to 0.999) |
| Sus-mesocolic | 0.999 (0.993 to 1.000) |
| Sub-mesocolic | 0.992 (0.968 to 0.998) |
| Pelvis | 0.998 (0.994 to 1.000) |
| Viscera | 0.975 (0.905 to 0.994) |
| ADP | 0.980 (0.921 to 0.995) |
Individual intra-class correlation coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter MTV of functional imaging Positron Emission Tomography. The functional imaging positron emission tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.482 (-0.079 to 0.833) |
| Sus-mesocolic | 0.450 (-0.165 to 0.824) |
| Sub-mesocolic | 0.137 (-0.606 to 0.698) |
| Pelvis | 0.747 (0.298 to 0.929) |
| Viscera | 0.023 (-0.586 to 0.616) |
| ADP | 0.881 (0.614 to 0.969) |
Average intra-class correlation coefficients (Absolute agreement) arepresented by location to evaluate the reliability between observers of quantization parameter MTV of functional imaging Positron Emission Tomography. The functional imaging Positron Emission Tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.650 (-0.173 to 0.909) |
| Sus-mesocolic | 0.621 (-0.396 to 0.904) |
| Sub-mesocolic | 0.241 (-3.081 to 0.822) |
| Pelvis | 0.855 (0.460 to 0.963) |
| Viscera | 0.044 (-2.827 to 0.762) |
| ADP | 0.937 (0.761 to 0.984) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter ADC of functional imaging Magnetic Resonance Imaging. The Magnetic Resonance Imaging will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.813 (0.292 to 0.960) |
| Sus-mesocolic | 0.922 (0.723 to 0.980) |
| Sub-mesocolic | 0.794 (0.393 to 0.944) |
| Pelvis | 0.178 (-0.567 to 0.718) |
| Viscera | 0.983 (0.925 to 0.996) |
| ADP | 0.974 (0.896 to 0.994) |
Average intra-class correlation coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter ADC of functional imaging Magnetic Resonance Imaging. The Magnetic Resonance Imaging will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.897 (0.452 to 0.980) |
| Sus-mesocolic | 0.960 (0.834 to 0.990) |
| Sub-mesocolic | 0.885 (0.564 to 0.971) |
| Pelvis | 0.302 (-2.620 to 0.836) |
| Viscera | 0.991 (0.961 to 0.998) |
| ADP | 0.987 (0.945 to 0.997) |
Individual Intra-class Correlation (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter SUVmax of functional imaging Positron Emission Tomography (PET). The functional imaging Positron Emission Tomography (PET) will be interpreted twice by radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.992 (0.969 to 0.998) |
| Sus-mesocolic | 0.884 (0.607 to 0.970) |
| Sub-mesocolic | 0.983 (0.934 to 0.996) |
| Pelvis | 0.998 (0.993 to 1.000) |
| Viscera | 0.317 (-0.332 to 0.770) |
| ADP | 0.977 (0.913 to 0.994) |
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter SUVmax of functional imaging Positron Emission Tomography (PET) . The functional imaging Positron Emission Tomography (PET) will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.996 (0.684 to 0.999) |
| Sus-mesocolic | 0.938 (0.755 to 0.985) |
| Sub-mesocolic | 0.991 (0.966 to 0.998) |
| Pelvis | 0.999 (0.996 to 1.000) |
| Viscera | 0.482 (-0.993 to 0.870) |
| ADP | 0.989 (0.954 to 0.997) |
Individual intra-class correlation coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter MTV of functional imaging Positron Emission Tomography (PET). The functional imaging Positron Emission Tomography (PET) will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.504 (-0.537 to 0.842) |
| Sus-mesocolic | 0.882 (0.618 to 0.969) |
| Sub-mesocolic | 0.210 (-0.439 to 0.719) |
| Pelvis | 0.699 (0.200 to 0.915) |
| Viscera | 0.486 (-0.137 to 0.840) |
| ADP | 0.994 (0.976 to 0.998) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter MTV of functional imaging Positron Emission Tomography (PET). The functional imaging Positron Emission Tomography (PET) will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.670 (-0.114 to 0.914) |
| Sus-mesocolic | 0.937 (0.764 to 0.984) |
| Sub-mesocolic | 0.347 (-1.564 to 0.837) |
| Pelvis | 0.823 (0.333 to 0.955) |
| Viscera | 0.654 (-0.318 to 0.913) |
| ADP | 0.997 (0.988 to 0.999) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.807 (0.321 to 0.958) |
| Sus-mesocolic | 0.340 (-0.154 to 0.757) |
| Sub-mesocolic | -0.080 (-0.703 to 0.564) |
| Pelvis | 0.566 (-0.055 to 0.871) |
| Viscera | 0.747 (0.240 to 0.931) |
| ADP | 0.863 (0.537 to 0.967) |
Average intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.893 (0.486 to 0.978) |
| Sus-mesocolic | 0.507 (-0.365 to 0.862) |
| Sub-mesocolic | 0.885 (0.564 to 0.971) |
| Pelvis | 0.723 (-0.116 to 0.931) |
| Viscera | 0.855 (0.387 to 0.964) |
| ADP | 0.926 (0.698 to 0.983) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter SUVmax of functional imaging positron emission tomography (PET) . The functional imaging positron emission tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Sus-mesocolic | 0.923 (0.738 to 0.980) |
| Sub-mesocolic | 0.953 (0.824 to 0.988) |
| Pelvis | 0.962 (0.856 to 0.990) |
| ADP | 0.942 (0.796 to 0.985) |
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter SUVmax of functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Sus-mesocolic | 0.960 (0.849 to 0.990) |
| Sub-mesocolic | 0.976 (0.904 to 0.994) |
| Pelvis | 0.981 (0.922 to 0.995) |
| ADP | 0.970 (0.887 to 0.992) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter MTV of functional imaging Positron Emission Tomography (MTV). The functional imaging Positron Emission Tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Sus-mesocolic | 0.957 (0.838 to 0.989) |
| Sub-mesocolic | 0.248 (-0.368 to 0.733) |
| Pelvis | 0.998 (0.992 to 0.999) |
| ADP | 0.943 (0.794 to 0.986) |
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter MTV of functional imaging Positron Emission Tomography (PET). The functional imaging Positron Emission Tomography will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Sus-mesocolic | 0.978 (0.912 to 0.995) |
| Sub-mesocolic | 0.398 (-1.163 to 0.846) |
| Pelvis | 0.999 (0.996 to 1.000) |
| ADP | 0.971 (0.885 to 0.993) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter ADC of functional imaging Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.961 (0.804 to 0.992) |
| Sus-mesocolic | 0.730 (0.265 to 0.924) |
| Sub-mesocolic | 0.862 (0.543 to 0.964) |
| Pelvis | 0.543 (0.059 to 0.861) |
| Viscera | 0.834 (0.491 to 0.955) |
| ADP | 1.000 (1.000 to 1.000) |
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability between observers of quantization parameter of ADC functional imaging Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently by 2 radiologists and 2 nuclear medicine specialists, in blind to results found by the other.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.980 (0.891 to 0.996) |
| Sus-mesocolic | 0.844 (0.419 to 0.960) |
| Sub-mesocolic | 0.926 (0.704 to 0.982) |
| Pelvis | 0.703 (0.126 to 0.925) |
| Viscera | 0.910 (0.659 to 0.977) |
| ADP | 1.000 (1.000 to 1.000) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter ADC of functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 1.000 (1.000 to 1.000) |
| Sus-mesocolic | 0.998 (0.991 to 0.999) |
| Sub-mesocolic | 1.000 (0.998 to 1.000) |
| Pelvis | 0.997 (0.987 to 0.999) |
| Viscera | 1.000 |
| ADP | 0.985 (0.942 to 0.996) |
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter SUVmax of functional imaging positron emission tomography (PET) . The imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 1.000 (1.000 to 1.000) |
| Sus-mesocolic | 0.999 (0.995 to 1.000) |
| Sub-mesocolic | 1.000 (0.999 to 1.000) |
| Pelvis | 0.998 (0.994 to 1.000) |
| Viscera | 1.000 |
| ADP | 0.992 (0.970 to 0.998) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameters functional imaging Positron Emission Tomography (MTV). The functional imaging Positron Emission Tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.987 (0.951 to 0.997) |
| Sus-mesocolic | 0.622 (0.041 to 0.890) |
| Sub-mesocolic | 0.493 (-0.212 to 0.858) |
| Pelvis | 0.847 (0.513 to 0.959) |
| Viscera | 0.042 (-0.572 to 0.623) |
| ADP | 0.934 (0.770 to 0.983) |
Average Intra-class Correlation Coefficients by Location (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameters MTV of functional imaging Positron Emission Tomography. The functional imaging Positron Emission Tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.993 (0.975 to 0.998) |
| Sus-mesocolic | 0.767 (0.079 to 0.942) |
| Sub-mesocolic | 0.660 (-0.538 to 0.924) |
| Pelvis | 0.917 (0.678 to 0.979) |
| Viscera | 0.080 (-2.668 to 0.771) |
| ADP | 0.966 (0.870 to 0.991) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.747 (0.136 to 0.944) |
| Sus-mesocolic | 0.894 (0.634 to 0.972) |
| Sub-mesocolic | 0.452 (-0.122 to 0.821) |
| Pelvis | 0.217 (-0.481 to 0.730) |
| Viscera | 0.639 (0.093 to 0.895) |
| ADP | 0.961 (0.839 to 0.991) |
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI) . The Magnetic Resonance Imaging will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.855 (0.240 to 0.971) |
| Sus-mesocolic | 0.944 (0.776 to 0.986) |
| Sub-mesocolic | 0.623 (-0.279 to 0.902) |
| Pelvis | 0.356 (-1.855 to 0.844) |
| Viscera | 0.780 (0.170 to 0.944) |
| ADP | 0.980 (0.912 to 0.995) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter SUV max of functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.893 (0.636 to 0.972) |
| Sus-mesocolic | 0.998 (0.994 to 1.000) |
| Sub-mesocolic | 0.993 (0.970 to 0.998) |
| Pelvis | 0.997 (0.987 to 0.999) |
| Viscera | 0.317 (-0.332 to 0.770) |
| ADP | 1.000 (1.000 to 1.000) |
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter SUVmax of functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.943 (0.777 to 0.986) |
| Sus-mesocolic | 0.999 (0.997 to 1.000) |
| Sub-mesocolic | 0.996 (0.985 to 0.999) |
| Pelvis | 0.999 (0.994 to 1.000) |
| Viscera | 0.482 (-0.993 to 0.870) |
| ADP | 0.482 (-0.993 to 0.870) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter MTV of functional imaging Positron Emission Tomography (PET). The functional imaging Positron Emission Tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.789 (0.384 to 0.942) |
| Sus-mesocolic | 0.898 (0.661 to 0.973) |
| Sub-mesocolic | 0.967 (0.866 to 0.992) |
| Pelvis | 0.329 (-0.311 to 0.774) |
| Viscera | 0.193 (-0.450 to 0.710) |
| ADP | 0.997 (0.988 to 0.999) |
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter MTV of functional imaging Positron Emission Tomography (PET). The functional imaging Positron Emission Tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.882 (0.555 to 0.970) |
| Sus-mesocolic | 0.946 (0.796 to 0.986) |
| Sub-mesocolic | 0.983 (0.928 to 0.996) |
| Pelvis | 0.495 (-0.903 to 0.873) |
| Viscera | 0.323 (-1.634 to 0.830) |
| ADP | 0.999 (0.994 to 1.000) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.607 (-0.155 to 0.909) |
| Sus-mesocolic | 0.613 (0.038 to 0.887) |
| Sub-mesocolic | -0.043 (-0.739 to 0.600) |
| Pelvis | 0.451 (-0.177 to 0.826) |
| Viscera | 0.792 (0.392 to 0.943) |
| ADP | 0.996 (0.984 to 0.999) |
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.755 (-0.368 to 0.952) |
| Sus-mesocolic | 0.760 (0.074 to 0.940) |
| Sub-mesocolic | -0.091 (-5.666 to 0.750) |
| Pelvis | 0.622 (-0.429 to 0.905) |
| Viscera | 0.884 (0.563 to 0.971) |
| ADP | 0.998 (0.992 to 1.000) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter SUVmax of functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 1.000 (1.000 to 1.000) |
| Sus-mesocolic | 1.000 |
| Sub-mesocolic | 1.000 (0.999 to 1.000) |
| Pelvis | 0.971 (0.891 to 0.993) |
| ADP | 1.000 |
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter SUVmax of functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Sus-mesocolic | 1.000 |
| Sub-mesocolic | 1.000 (0.998 to 1.000) |
| Pelvis | 0.944 (0.803 to 0.986) |
| ADP | 1.000 |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter MTV functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Sus-mesocolic | 0.794 (0.385 to 0.944) |
| Sub-mesocolic | 0.794 (0.322 to 0.950) |
| Pelvis | 0.975 (0.908 to 0.994) |
| ADP | 0.987 (0.950 to 0.997) |
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observer of quantization parameter MTV functional imaging positron emission tomography (PET). The functional imaging positron emission tomography will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Sus-mesocolic | 0.885 (0.556 to 0.971) |
| Sub-mesocolic | 0.885 (0.487 to 0.974) |
| Pelvis | 0.987 (0.952 to 0.997) |
| ADP | 0.993 (0.974 to 0.998) |
Individual Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter ADC of functional imaging Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.930 (0.703 to 0.986) |
| Sus-mesocolic | 0.654 (0.038 to 0.910) |
| Sub-mesocolic | 0.767 (0.302 to 0.937) |
| Pelvis | 0.088 (-0.467 to 0.639) |
| Viscera | 0.686 (0.184 to 0.910) |
| ADP | 0.804 (0.320 to 0.957) |
Average Intra-class Correlation Coefficients (Absolute agreement) are presented by location to evaluate the reliability within observers of quantization parameter ADC of Magnetic Resonance Imaging (MRI). The Magnetic Resonance Imaging will be interpreted independently twice by the same radiologist and nuclear medicine specialist.
| proportion of agreement | Functional Imaging |
|---|---|
| Supra-diaphragmatic | 0.964 (0.826 to 0.993) |
| Sus-mesocolic | 0.791 (0.073 to 0.953) |
| Sub-mesocolic | 0.868 (0.463 to 0.967) |
| Pelvis | 0.162 (-1.753 to 0.780) |
| Viscera | 0.814 (0.311 to 0.953) |
| ADP | 0.891 (0.485 to 0.978) |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy). In other words, without paying attention to assessment times and the location of the lesion, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyse. The appearance of new lesions (not present at baseline) has not been taken into account in the calculation of relative variations. The disappearance of pre-existing lesions at baseline has been taken into account in the calculation of relative variations. Relative variations has been calculated as the difference between the values collected after 1 cycle of chemotherapy and the pre-therapeutic value divided by the pre-therapeutic value.
| Spearman's correlation coefficient | Functional Imaging |
|---|---|
| Spearman correlation test statistics between CA125 and relative variation of PET parameter SUVmax | -0.091 (-0.679 to 0.575) |
| Spearman correlation test statistics between CA125 and relative variation of PET parameter MTV | -0.030 (-0.647 to 0.612) |
| Spearman correlation test statistics between CA125 and relative variation of PET parameter SUVN | -0.212 (-0.737 to 0.491) |
| Spearman correlation test statistics between CA125 and relative variation of PET parameter SUL | -0.212 (-0.737 to 0.491) |
| Spearman correlation test statistics between CA125 and relative variation of PET parameter TLG | -0.164 (-0.715 to 0.526) |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy). In other words, without paying attention to assessment times and the location of the lesion, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyse. The appearance of new lesions (not present at baseline) has not been taken into account in the calculation of relative variations. The disappearance of pre-existing lesions at baseline has been taken into account in the calculation of relative variations. Relative variations has been calculated as the difference between the values collected after 4 cycles of chemotherapy and the pre-therapeutic value divided by the pre-therapeutic value.
| Spearman's correlation coefficient | Functional Imaging |
|---|---|
| Spearman correlation test statistics between CA125 and relative variation of PET parameter SUVmax | 0.811 (0.082 to 0.967) |
| Spearman correlation test statistics between CA125 and relative variation of PET parameter MTV | 0.775 (-0.012 to 0.960) |
| Spearman correlation test statistics between CA125 and relative variation of PET parameter SUVN | 0.811 (0.082 to 0.967) |
| Spearman correlation test statistics between CA125 and relative variation of PET parameter SUL | 0.811 (0.082 to 0.967) |
| Spearman correlation test statistics between CA125 and relative variation of PET parameter TLG | 0.775 (-0.012 to 0.960) |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. The appearance of new lesions (not present at baseline) has not been taken into account in the calculation of relative variations. The disappearance of pre-existing lesions at baseline has been taken into account in the calculation of relative variations. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles of chemotherapy and the pre-therapeutic value divided by the pre-therapeutic value.
| Spearman's correlation coefficient | Functional Imaging |
|---|---|
| Relative variations between pre-therapeutic and after one cycle of chemotherapy | 0.103 (-0.567 to 0.685) |
| Relative variations between pre-therapeutic and after four cycles of chemotherapy | -0.571 (-0.919 to 0.361) |
| Participants | Functional Imaging |
|---|---|
| Yes | 10 |
| No | 0 |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
| change in relative variance | Functional Imaging |
|---|---|
| Partial response | -25.4 ± 33.1 |
| Stable disease | -9.6 ± 29.8 |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. RRelative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
| change in relative variance | Functional Imaging |
|---|---|
| Partial response | -67.3 ± 29.3 |
| Stable disease | -11.3 ± 31.1 |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
| change in relative variance | Functional Imaging |
|---|---|
| Partial response | -94.7 ± 11.4 |
| Stable disease | 12.9 ± 52.9 |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
| change in relative variance | Functional Imaging |
|---|---|
| Partial response | -38.5 ± 47.6 |
| Stable disease | -3.3 ± 5.4 |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
| change in relative variance | Functional Imaging |
|---|---|
| Partial response | -21.8 ± 28.8 |
| Stable disease | -15.6 ± 22.1 |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
| change in relative variance | Functional Imaging |
|---|---|
| Partial response | -65.2 ± 29.4 |
| Stable disease | -16.2 ± 30.2 |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
| change in relative variance | Functional Imaging |
|---|---|
| Partial response | -63.5 ± 52.4 |
| Stable disease | -15.2 ± 12.9 |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
| change in relative variance | Functional Imaging |
|---|---|
| Partial response | -97.7 ± 9.4 |
| Stable disease | -7.5 ± 18.2 |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
| change in relative variance | Functional Imaging |
|---|---|
| Partial response | -24.9 ± 31.9 |
| Stable disease | -21.8 ± 11.4 |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
| change in relative variance | Functional Imaging |
|---|---|
| Partial response | -66.9 ± 29.0 |
| Stable disease | -14.7 ± 33.8 |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
| change in relative variance | Functional Imaging |
|---|---|
| Partial response | 9.3 ± 209.7 |
| Stable disease | 4.3 ± 25.1 |
In this section, only the maximum values of the PET parameters (SUVmax, MTV, SUVN, SUL, TLG) and the minimum values of the MRI parameters (ADC) of each patient were taken into account for all lesions present at each evaluation time (pre-therapy, after 1 cycle of chemotherapy, after 4 cycles of chemotherapy. In other words, for each patient, the highest value of SUVmax, MTV, SUVN, SUL, TLG and the lowest ADC value was taken into account in the analyses. Relative variations has been calculated as the difference between the values collected after 1 or 4 cycles (C1 or C4) of chemotherapy and the pre-therapeutic value (C0) divided by the pre-therapeutic value (C0).
| change in relative variance | Functional Imaging |
|---|---|
| Partial response | 38.6 ± 274.5 |
| Stable disease | -18.0 ± 40.1 |
The Fagotti score ranges from 0 to 14 and is used to evaluate the peritoneal damage of patients. This score was collected during pretherapy and after 4 cycles of chemotherapy. The higher the stage number is, the further the cancer has spread. The Fagotti questionnaire has 7 items. A subscale value of 0 or 2 is assigned depending on whether the disease is present in those specific sites : large omentum, peritoneal carcinosis , diaphragmatic carcinosis, mesenteric retraction, intestinal infiltration, stomach infiltration,liver metastases. The sum of subscale values corresponds to Fagotti score.
| Participants | Functional Imaging |
|---|---|
| 4 | 2 |
| 8 | 4 |
| 10 | 2 |
| 12 | 1 |
| Missing | 1 |
TThe Fagotti score ranges from 0 to 14 and is used to evaluate the peritoneal damage of patients. This score was collected during pretherapy and after 4 cycles of chemotherapy. The higher the stage number is, the further the cancer has spread. The Fagotti questionnaire has 7 items. A subscale value of 0 or 2 is assigned depending on whether the disease is present in those specific sites : large omentum, peritoneal carcinosis , diaphragmatic carcinosis, mesenteric retraction, intestinal infiltration, stomach infiltration,liver metastases. The sum of subscales corresponds to Fagotti score.
| Participants | Functional Imaging |
|---|---|
| 0 | 1 |
| 2 | 1 |
| 4 | 2 |
| 6 | 2 |
| 8 | 3 |
| 10 | 1 |
| percentage of patients | Functional Imaging |
|---|---|
| Overall Survival | 90 (47.3 to 98.5) |
| percentage of patients | Functional Imaging |
|---|---|
| 9 months | 90.0 (47.3 to 98.5) |
| 13 months | 78.8 (38.1 to 94.3) |
| 14 months | 67.5 (29.1 to 88.2) |
Collected over All adverse events are recorded from the first visit (J0 inclusion) until 4 weeks after the third PET/MRI examination. Beyond this period, only SAE likely to be related to the research or the medical device or to the procedure of implementation of the medical device are reported.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Functional Imaging | 1/11 (9.1%) | 3/11 (27.3%) | 11/11 (100%) |
| Event | Functional Imaging |
|---|---|
| AnemiaBlood and lymphatic system disorders | 1/11 |
| Colonic obstructionGastrointestinal disorders | 1/11 |
| VomitingGastrointestinal disorders | 1/11 |
| SepsisInfections and infestations | 1/11 |
| Event | Functional Imaging |
|---|---|
| AnemiaBlood and lymphatic system disorders | 3/11 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/11 |
| AscitesGastrointestinal disorders | 2/11 |
| ConstipationGastrointestinal disorders | 2/11 |
| DiarrheaGastrointestinal disorders | 2/11 |
| NauseaGastrointestinal disorders | 2/11 |
| FatigueGeneral disorders | 2/11 |
| FeverGeneral disorders | 2/11 |
| Allergic reactionImmune system disorders | 2/11 |
| Bronchial infectionInfections and infestations | 2/11 |
| Age, Continuous(years) | Functional Imaging |
|---|---|
| Median | 67.0 (41.8 to 77.3) |
| Sex: Female, Male(Participants) | Functional Imaging |
|---|---|
| Female | 11 |
| Male | 0 |
| Race and Ethnicity Not Collected(Participants) | Functional Imaging |
|---|
| Proven epithelial carcinoma of gynaecological origin(Participants) | Functional Imaging |
|---|---|
| Yes | 11 |
| No | 0 |
| Location of the tumour(Participants) | Functional Imaging |
|---|---|
| Ovaries | 9 |
| Trunk | 1 |
| Primitive peritoneal | 1 |
| Histological type(Participants) | Functional Imaging |
|---|---|
| Serous | 11 |
| Other type | 0 |
| Stage of the tumour(Participants) | Functional Imaging |
|---|---|
| III-c | 5 |
| IV | 6 |
| Total Fagotti Score(Participants) | Functional Imaging |
|---|---|
| 4 | 2 |
| 8 | 4 |
| 10 | 3 |
| 12 | 1 |
| Not available | 1 |
6 further baseline measures are reported on the registry.
Plan to share: No
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Bergonié